Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment

Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes

(2021) Alfie T. Baker et al.   JOURNAL OF IMMUNOLOGY

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives

(2021) Yang Wu et al.   Frontiers in Oncology

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

(2020) John D. Martin et al.   Nature Reviews Clinical Oncology

CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint

(2020) Miao Yu et al.   Nature Communications

Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma

(2020) Handan Xiang et al.   Cancer Immunology Research

Cross-Talk Between the Tumor Microenvironment, Extracellular Matrix, and Cell Metabolism in Cancer

(2020) Mona Nazemi et al.   Frontiers in Oncology

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

(2020) Constance J. Martin et al.   Science Translational Medicine

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

(2020) Jenny H. Lee et al.   Nature Communications

Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer

(2020) Yann Kieffer et al.   Cancer Discovery

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers

(2020) Jerry B. Harvey et al.   Frontiers in Immunology

Future Challenges in Cancer Resistance to Immunotherapy

(2020) Marit J. van Elsas et al.   Cancers

Heterogeneity of cancer‐associated fibroblasts: Opportunities for precision medicine

(2020) Ryu Kanzaki et al.   CANCER SCIENCE

Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy

(2020) Richard Barrett et al.   CURRENT OPINION IN IMMUNOLOGY

Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer

(2020) Sunny Z Wu et al.   EMBO JOURNAL

A deep learning model to predict RNA-Seq expression of tumours from whole slide images

(2020) Benoît Schmauch et al.   Nature Communications

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

(2020) Marta Trüb et al.   Journal for ImmunoTherapy of Cancer

The CCL5/CCR5 Axis in Cancer Progression

(2020) Donatella Aldinucci et al.   Cancers

Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions

(2020) Shweta Joshi   Cancers

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook

(2020) Lena Horvath et al.   Molecular Cancer

TGF-β suppresses type 2 immunity to cancer

(2020) Ming Liu et al.   NATURE

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

(2020) Shun Li et al.   NATURE

Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies

(2020) Rana Mhaidly et al.   SEMINARS IN IMMUNOLOGY

Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma

(2020) Zhaohui Chen et al.   Nature Communications

IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy

(2020) Rebekka Weber et al.   CELLULAR IMMUNOLOGY

TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

(2020) Angelo L. Grauel et al.   Nature Communications

Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy

(2020) Richard Lee Barrett et al.   eLife

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

(2019) Jason J. Luke et al.   CLINICAL CANCER RESEARCH

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma

(2019) Andrew J. Gunderson et al.   PLoS One

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

(2019) Tina Gruosso et al.   JOURNAL OF CLINICAL INVESTIGATION

In search of definitions: Cancer-associated fibroblasts and their markers

(2019) Martin Nurmik et al.   INTERNATIONAL JOURNAL OF CANCER

Cancer Metabolism Drives a Stromal Regenerative Response

(2019) Simon Schwörer et al.   Cell Metabolism

Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

(2019) Micol Eleonora Fiori et al.   Molecular Cancer

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

(2019) Li-Chuan Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

(2019) Christina Claus et al.   Science Translational Medicine

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts

(2019) Ela Elyada et al.   Cancer Discovery

Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells

(2019) Laia Gorchs et al.   Frontiers in Immunology

Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins

(2019) Cédric Zeltz et al.   SEMINARS IN CANCER BIOLOGY

The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment

(2019) Lea Monteran et al.   Frontiers in Immunology

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

(2019) Johannes Griss et al.   Nature Communications

Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy

(2019) Claudia X Dominguez et al.   Cancer Discovery

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

(2019) Lawrence Fong et al.   Cancer Discovery

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

(2019) Hui-Ching Wang et al.   Frontiers in Oncology

Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer

(2018) Ana Costa et al.   CANCER CELL

Cancer-stimulated CAFs enhance monocyte differentiation and pro-tumoral TAM activation via IL-6 and GM-CSF secretion

(2018) Haaglim Cho et al.   CLINICAL CANCER RESEARCH

HALO-109–301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer

(2018) Gary J Doherty et al.   Future Oncology

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

The perivascular origin of pathological fibroblasts

(2018) Selene E. Di Carlo et al.   JOURNAL OF CLINICAL INVESTIGATION

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

(2018) Sunil R. Hingorani et al.   JOURNAL OF CLINICAL ONCOLOGY

A2AAdenosine Receptor Gene Deletion or Synthetic A2AAntagonist Liberate Tumor-Reactive CD8+T Cells from Tumor-Induced Immunosuppression

(2018) Jorgen Kjaergaard et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment

(2018) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes

(2018) Arthur Winer et al.   MOLECULAR CANCER THERAPEUTICS

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Phenotype molding of stromal cells in the lung tumor microenvironment

(2018) Diether Lambrechts et al.   NATURE MEDICINE

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

(2018) Yan Lan et al.   Science Translational Medicine

Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma

(2018) Yusheng Cheng et al.   Cell Death & Disease

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy

(2018) Marco B. Schaaf et al.   Cell Death & Disease

miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers

(2018) Anne-Marie Givel et al.   Nature Communications

Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells

(2018) Matthew A. Lakins et al.   Nature Communications

Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts

(2018) Linda Ziani et al.   Frontiers in Immunology

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

TGF-β in T Cell Biology: Implications for Cancer Immunotherapy

(2018) Amina Dahmani et al.   Cancers

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

(2018) Stephen B. Willingham et al.   Cancer Immunology Research

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

(2018) Derya Kabacaoglu et al.   Frontiers in Immunology

Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma

(2018) Cindy Neuzillet et al.   JOURNAL OF PATHOLOGY

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

(2018) Ankur Chakravarthy et al.   Nature Communications

Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing

(2018) Michael Bartoschek et al.   Nature Communications

IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma

(2018) Giulia Biffi et al.   Cancer Discovery

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer

(2018) Franziska Eckert et al.   Frontiers in Immunology

Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression

(2018) Subramanyam Dasari et al.   Cancers

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models

(2017) Shinichi Esaki et al.   INTERNATIONAL JOURNAL OF CANCER

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

(2017) Tomohiro Nishina et al.   INVESTIGATIONAL NEW DRUGS

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

(2017) Daniel Öhlund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors

(2017) Huipeng Li et al.   NATURE GENETICS

Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade

(2017) Dirk Zboralski et al.   Cancer Immunology Research

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

(2017) Brian Hutzen et al.   Molecular Therapy-Oncolytics

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas

(2016) Yoshihiro Mezawa et al.   CELL AND TISSUE RESEARCH

Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

(2016) S. R. Hingorani et al.   CLINICAL CANCER RESEARCH

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

(2016) Jonathan Oh et al.   GYNECOLOGIC ONCOLOGY

Hyaluronan synthase 2 expressed by cancer-associated fibroblasts promotes oral cancer invasion

(2016) Ziwen Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma

(2016) Elisabete F Carapuça et al.   JOURNAL OF PATHOLOGY

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

(2016) S Lefort et al.   ONCOGENE

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma

(2016) Andrew H. Ko et al.   PANCREAS

Pericyte–fibroblast transition promotes tumor growth and metastasis

(2016) Kayoko Hosaka et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation

(2016) J-t Cheng et al.   Oncogenesis

Stromal Myofibroblasts Are Associated with Poor Prognosis in Solid Cancers: A Meta-Analysis of Published Studies

(2016) Liu Liu et al.   PLoS One

Tumor-Derived Osteopontin Reprograms Normal Mammary Fibroblasts to Promote Inflammation and Tumor Growth in Breast Cancer

(2015) Y. Sharon et al.   CANCER RESEARCH

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer

(2015) L. Ryner et al.   CLINICAL CANCER RESEARCH

Translational Implications of Tumor Heterogeneity

(2015) M. Jamal-Hanjani et al.   CLINICAL CANCER RESEARCH

A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice

(2015) Jinxu Fang et al.   INTERNATIONAL JOURNAL OF CANCER

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

(2015) Sachet A Shukla et al.   NATURE BIOTECHNOLOGY

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

(2015) Alexandre Calon et al.   NATURE GENETICS

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment

(2015) Thomas F. Gajewski   SEMINARS IN ONCOLOGY

Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy

(2015) H. Michael Shepard   Frontiers in Oncology

Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

(2014) Mara H. Sherman et al.   CELL

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Is there new hope for therapeutic matrix metalloproteinase inhibition?

(2014) Roosmarijn E. Vandenbroucke et al.   NATURE REVIEWS DRUG DISCOVERY

The two faces of IL-6 in the tumor microenvironment

(2014) Daniel T. Fisher et al.   SEMINARS IN IMMUNOLOGY

Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction

(2013) T Nagasaki et al.   BRITISH JOURNAL OF CANCER

Adipocyte-Derived Fibroblasts Promote Tumor Progression and Contribute to the Desmoplastic Reaction in Breast Cancer

(2013) L. Bochet et al.   CANCER RESEARCH

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

(2013) Jérôme Galon et al.   JOURNAL OF PATHOLOGY

MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells

(2013) P. Leone et al.   JNCI-Journal of the National Cancer Institute

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis

(2013) Noriko Komatsu et al.   NATURE MEDICINE

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

(2013) A. Neesse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

(2013) L.-C. S. Wang et al.   Cancer Immunology Research

Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation

(2012) Alexandre Calon et al.   CANCER CELL

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

(2012) Michael A Jacobetz et al.   GUT

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

(2012) Hélène Salmon et al.   JOURNAL OF CLINICAL INVESTIGATION

Microenvironment and tumor progression of melanoma: New therapeutic prospectives

(2012) Gerardo Botti et al.   Journal of Immunotoxicology

Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor Growth

(2011) Michael Quante et al.   CANCER CELL

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

(2011) Adam T. Waickman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Retinoic Acid–Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt–β-Catenin Signaling to Slow Tumor Progression

(2011) Fieke E.M. Froeling et al.   GASTROENTEROLOGY

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

(2011) Daniel T. Fisher et al.   JOURNAL OF CLINICAL INVESTIGATION

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization

(2011) J. T. O'Connell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: Ready for prime time?

(2010) Stanley Zucker et al.   CANCER BIOLOGY & THERAPY

Reciprocal Functional Modulation of the Activation of T Lymphocytes and Fibroblasts Derived from Human Solid Tumors

(2010) J. L. Barnas et al.   JOURNAL OF IMMUNOLOGY

Pathways mediating VEGF-independent tumor angiogenesis

(2009) Napoleone Ferrara   CYTOKINE & GROWTH FACTOR REVIEWS

Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice

(2009) Angélica M. Santos et al.   JOURNAL OF CLINICAL INVESTIGATION

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

(2009) Franck Pagès et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

The role of endothelial-to-mesenchymal transition in cancer progression

(2008) S Potenta et al.   BRITISH JOURNAL OF CANCER

Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts

(2008) E. Ostermann et al.   CLINICAL CANCER RESEARCH

Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting

(2008) Kristian Pietras et al.   PLOS MEDICINE